西格列汀对初发2型糖尿病患者胰岛B细胞功能的影响

摘要

目的：研究西格列汀对初发2型糖尿病患者胰岛B细胞功能的影响。方法选择我院门诊2型糖尿病患者69例,随机分为对照组和试验组,对照组35例,试验组34例,对照组予二甲双胍治疗,试验组予二甲双胍、西格列汀治疗,12周后比较治疗前后两组患者空腹血糖( FPG )、餐后2 h 血糖( PPG )、糖化血红蛋白(HbA1c)、体重指数(BMI)、空腹胰岛素(Fins)、餐后2 h胰岛素(Pins)。结果两组治疗前各项指标比较差异无统计学意义(P>0．05),治疗后,两组FPG、PPG、HbA1c、BMI均较治疗前显著下降(P<0．05)。与对照组相比,试验组FPG、PPG、HbA1c降低更明显(P<0．05),Fins、Pins水平升高更显著(P<0．05)。结论西格列汀能明显改善初发2型糖尿病患者的胰岛B细胞功能,在临床应用中安全有效。%Objective To explore the effect of sitagliptin on B cell function in the treatment of newly diag-nosed type 2 diabetes. Methods 69 outpatients with type 2 diabetes in our hospital were randomly divided into control group (n=35) and trial group (n=34),patients were treated with metformin without or with sitagliptin respectively. Two groups were followed up for 12 weeks. Fasting plasma glucose ( FPG) ,2 h postprandial plasma glucose ( PPG) , glycosylated hemoglobin (HbA1c),change in body mass index (BMI),fasting plasma insulin (Fins),2 h postprandial plasma insulin ( Pins) were recorded in the two groups before and after treatment. Results There was no significant difference between the two groups in FPG,PPG,HbA1c,BMI,Fins,Pins before treatment (P>0. 05). Compared with the baseline,FPG,PPG,HbA1c,BMI in both two groups declined significantly (P <0. 05). After treatment,FPG, PPG,HbA1c were significantly lower,and Fins,Pins were significantly higher in treatment group compared with those in control group (P<0. 05). Conclusion Sitagliptin could obviously improve B cell function in the treatment of new-ly diagnosed type 2 diabetes,it is safe and effective in clinical application.